BLA 761052 · Biomarin Pharm
Brineura
Cerliponase Alfa · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 27, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
536
391 serious, 26 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate BRINEURA in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue BRINEURA and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ]. WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Aug 5, 2024.
BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency. BRINEURA is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency. ( 1 )
Mechanism: CLN2 disease is a neurodegenerative disease caused by deficiency of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1), which catabolizes polypeptides in the CNS. TPP1 has no known substrate specificity. Deficiency in TPP1 activity results in the accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system (CNS), leading to progressive decline in motor function. Cerliponase alfa (rhTTP1), a proenzyme, is taken up by target cells in the CNS and is translocated to the lysosomes through the Cation Independent Mannose-6-Phosphate Receptor (CI-MPR,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2024 Supplement 14 · Efficacy OrphanLetterLabel
- Apr 27, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- BRINEURA · CERLIPONASE ALFA 30MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cerliponase Alfa" as an intervention, any sponsor and status, largest first.
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01907087 · 24 participants · Start Sep 2013 · Primary completion Nov 2015
Drug: BMN 190 · For: Jansky-Bielschowsky Disease; Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 and 1 more
Sites: Columbus, Ohio; Hamburg, Germany; Rome, Italy · 5 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT02485899 · 23 participants · Start Feb 2015 · Primary completion Dec 10, 2020
Drug: BMN 190 · For: Jansky-Bielschowsky Disease; Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 and 2 more
Sites: Columbus, Ohio; Hamburg, Germany; Rome, Italy · 4 sites in all
BioMarin PharmaceuticalBioMarin (BMRN)
NCT02678689 · 14 participants · Start Jan 22, 2016 · Primary completion Apr 20, 2022
Drug: BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) · For: Jansky-Bielschowsky Disease; Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 and 2 more
Sites: Columbus, Ohio; Hamburg, Germany; Rome, Italy · 4 sites in all
- Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2Active, not recruiting
David L Rogers, MDAcademic, hospital or other
NCT05152914 · 5 participants (planned) · Start Nov 1, 2021 · Primary completion Mar 4, 2026
Drug: Cerliponase Alfa · For: Neuronal Ceroid Lipofuscinosis Type 2
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia91
- seizure79
- vomiting38
- device related infection31
- device leakage28
- csf culture positive26
- pneumonia26
- headache22
- drug ineffective20
- off label use18
- device occlusion16
- general physical health deterioration16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 9 |
| 2018 | 29 |
| 2019 | 46 |
| 2020 | 52 |
| 2021 | 83 |
| 2022 | 84 |
| 2023 | 73 |
| 2024 | 52 |
| 2025 | 71 |
| 2026 | 37 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of Neuronal Ceroid Lipofuscinosis Type 2 with Cerliponase Alfa: A Systematic Review and Single-Arm Meta-Analysis of Two Studies.
Oliveira JA, Saddique MN, Qadri M, et al. · J Child Neurol 2026 · Systematic Review, Meta-Analysis
- Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.
Cherukuri A, Cahan H, de Hart G, et al. · Clin Immunol 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
Schulz A, Ajayi T, Specchio N, et al. · N Engl J Med 2018 · Clinical Trial, Multicenter Study
- Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
Kim A, Grover A, Hammon K, et al. · Clin Transl Sci 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data.
Specchio N, Gissen P, de Los Reyes E, et al. · PLoS One 2024 · Clinical Trial, Phase II, Comparative Study
- Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.
Hammon K, de Hart G, Vuillemenot BR, et al. · Clin Transl Sci 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.